REFERENCE
Remák E, Charbonneau C, Négrier S, Kim ST, Motzer RJ.Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. Journal of Clinical Oncology 26: 3995-4000, No. 24, 20 Aug 2008
Rights and permissions
About this article
Cite this article
First-line sunitinib cost-effective alternative to interferon-α in renal cancer. Pharmacoecon. Outcomes News 561, 1 (2008). https://doi.org/10.2165/00151234-200805610-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805610-00001